BioWorld

Sep. 15, 2004

View Archived Issues

YM Funding Gets Up To C$23M For Tesmilifene Phase III Trials

As its Phase III tesmilifene trial continues to enroll breast cancer patients, YM BioSciences Inc. entered a bought-deal agreement that could result in gross proceeds for the company of C$23 million (US$17.8 million). (BioWorld Today) Read More

Genospectra Series C Raises $16.4M For Next PQB Steps

Read More

FDA, Industry Ask What Makes Biogenerics Work?

Read More

FDA's Decision On Omnitrope Points To Biogeneric Haziness

Read More

Other News To Note

Read More

Appointments And Advancements

Read More